Improving Overall Survival and Quality of Life in Patients with Prostate Cancer and Neuroendocrine Tumors Using <sup>177</sup>Lu-iPSMA and <sup>177</sup>Lu-DOTATOC: Experience after 905 Treatment Doses

Improving Overall Survival and Quality of Life in Patients with Prostate Cancer and Neuroendocrine Tumors Using <sup>177</sup>Lu-iPSMA and <sup>177</sup>Lu-DOTATOC: Experience after 905 Treatment Doses

<sup>177</sup>Lu-iPSMA is a novel radioligand developed at ININ-Mexico with a high affinity for the PSMA protein heavily expressed in cancer cells of approximately 95% of patients with metastatic castration-resistant prostate cancer (mCRPC). <sup>177</sup>Lu-DOTATOC is a pate...

Full description

Bibliographic Details
Main Authors: Myrna Luna-Gutiérrez, Rodrigo Hernández-Ramírez, Airam Soto-Abundiz, Osvaldo García-Pérez, Alejandra Ancira-Cortez, Sergio López-Buenrostro, Brenda Gibbens-Bandala, Irma Soldevilla-Gallardo, Nancy Lara-Almazán, Melissa Rojas-Pérez, Blanca Ocampo-García, Erika Azorín-Vega, Clara Santos-Cuevas, Guillermina Ferro-Flores
Format: Article
Language:English
Published: MDPI AG 2023-07-01
Series:Pharmaceutics
Subjects:
PSMA
somatostatin receptors
lutetium-177
<sup>177</sup>Lu-DOTATOC
<sup>177</sup>Lu-iPSMA
Online Access:https://www.mdpi.com/1999-4923/15/7/1988

Internet

https://www.mdpi.com/1999-4923/15/7/1988

Similar Items